- Shady Grove Fertility
- United States of America
We and selected partners, use cookies or similar technologies as specified in the cookie policy and privacy policy.
You can consent to the use of such technologies by closing this notice.
Customise your preferences for any tracking technology
The following allows you to customize your consent preferences for any tracking technology used to help us achieve the features and activities described below. To learn more about how these trackers help us and how they work, refer to the cookie policy. You may review and change your preferences at any time.
These trackers are used for activities that are strictly necessary to operate or deliver the service you requested from us and, therefore, do not require you to consent.
These trackers help us to deliver personalized marketing content and to operate, serve and track ads.
These trackers help us to deliver personalized marketing content to you based on your behaviour and to operate, serve and track social advertising.
These trackers help us to measure traffic and analyze your behaviour with the goal of improving our service.
These trackers help us to provide a personalized user experience by improving the quality of your preference management options, and by enabling the interaction with external networks and platforms.
Recent Comments
Interesting article. I think the issue with the vaginal progesterone group is that it was not given long enough and at enough dosage. We transfer of the 6th day of progesterone and use endometrin tid.
Our live birth rates for 2014 and 2015 without the use of PGS are greater than the clinical pregnancy rates you report.
Age LBR N
<35 42.6% 357
35-37 37.4% 115
38-40 39.1% 46
I realize this is an interim report and maybe I did not read closely enough but I did not see data on mean age of patients or implantation.
Sherif G Awadalla, M. D.
Institute for Reproductive Health
Cincinnati, OH
Thank you very much for your comments, Dr. Awadalla.
PGS was an exclusion for the current study, which likely accounts for some of the difference you describe between your population and ours.
We fully acknowledge that the optimal duration of progesterone exposure (whether IM or vaginal) has not been established. That said, in the current study, the group that received both vaginal and IM progesterone had the same duration of progesterone exposure as the group that received vaginal progesterone only. However, the group receiving vaginal and IM progesterone had a significantly higher ongoing pregnancy rate. The only difference between the two protocols was the addition of IM progesterone once every third day.
As for the ages of the patients they are found in Table 2 and were a mean age of 33.2-33.5y at time of vitrification.
Please logon to discuss for the live Journal Club on Thursday evening March 15, 2018 at 7p.
Gratefully
Kate Devine, MD
SGF
Washington DC
Thank you Dr. Hill! We too are looking forward to discussing our findings at the live F&S journal club on March 15. The last delivery outcome for the study should be known at the beginning of April 2018, and we plan to analyze these data straight away once the outcome data are complete. Hopefully we will be able to report our findings at the national ASRM meeting this year.